Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Partial-Blind, Parallel-Group, Active- and Vehicle-Controlled, Multicenter Study of the Safety and Efficacy of ACZONE™ (Dapsone) Gel, 5% in Subjects With Papulopustular Rosacea

NCT00249782 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT00249782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00249782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Partial-Blind, Parallel-Group, Active- and Vehicle-Controlled, Multicenter Study of the Safety and Efficacy of ACZONE™ (Dapsone) Gel, 5% in Subjects With Papulopustular Rosacea
Lead sponsor
Allergan
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
May 31, 2006
Enrollment
400 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

rosacea